On May 19, 2022, Shreeram Aradhye, M.D., a member of the board of directors of Axcella Health Inc. notified the company of his resignation from the board, effective immediately. Dr. Aradhye's resignation was not the result of a disagreement with the company on any matter relating to the company's operations, policies or practices. Effective as of his resignation, Dr. Aradhye is no longer a member of the Board or any of its committees.

On May 25, 2022, Alison D. Schecter, M.D., stepped down as the company's President of Research and Development to pursue other opportunities, effective immediately. Dr. Schecter joined the company on March 2, 2021. On May 19, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Paul J. Sekhri and Michael Rosenblatt, M.D. to join the Board, effective immediately.

The Board determined that Mr. Sekhri and Dr. Rosenblatt are each independent under the listing standards of Nasdaq and the company's corporate governance guidelines. Mr. Sekhri will serve as a Class II director with a term expiring at the annual meeting of stockholders to be held in 2024. Dr. Rosenblatt will serve as a Class I director with a term expiring at the annual meeting of stockholders to be held in 2023.

Paul J. Sekhri currently serves on the board of directors of Longboard Pharmaceuticals Inc. (Nasdaq: LBPH), Ipsen S.A., Veeva Systems Inc., Compugen Ltd. and Pharming Group N.V. (Nasdaq: PHAR), where he is Chairman. Mr. Sekhri has most recently served as the President and Chief Executive Officer of eGenesis Inc. Michael Rosenblatt, M.D. is currently a Senior Partner at Flagship Pioneering. From September 2016 to December 2020, Dr. Rosenblatt served as Chief Medical Officer of Flagship Pioneering.

From December 2009 to June 2016, he served as the Executive Vice President and Chief Medical Officer of Merck & Co. Inc. Dr. Rosenblatt serves on the board of directors of Rubius Therapeutics Inc. (Nasdaq: RUBY) and Azenta Inc. (Nasdaq: AZTA) and has previously served on the board of directors of Radius Health Inc. (Nasdaq: RDUS). Dr. Rosenblatt received an M.D. from Harvard Medical School and an A.B. in chemistry from Columbia University.

The stockholders of the company elected Martin Hendrix, Ph.D as Class III directors to the board of directors of the company.